HDFCBANK 1,825.25 +19.30 (1.07%) 
RELIANCE 1,278.40 +5.85 (0.46%) HINDUNILVR 2,236.75 -7.10 (-0.32%) TCS 3,651.65 +16.15 (0.44%) HDFC 2,729.95 -17.05 (-0.62%) INFY 1,603.55 +5.40 (0.34%) ITC 409.40 +2.35 (0.58%) BAJFINANCE 8,986.00 +121.05 (1.37%) ICICIBANK 1,336.75 +1.35 (0.10%) SBIN 772.40 +9.05 (1.19%) AXISBANK 1,098.50 +2.90 (0.26%) MARUTI 11,721.65 -10.05 (-0.09%) NESTLEIND 2,240.15 -3.20 (-0.14%) BHARTIARTL 1,723.35 -14.20 (-0.82%) LT 3,503.30 +60.70 (1.76%) DMART 4,064.85 +120.85 (3.06%) HCLTECH 1,626.80 -6.50 (-0.40%) SUNPHARMA 1,731.20 -26.50 (-1.51%) BAJAJFINSV 2,005.40 +62.70 (3.23%) NTPC 360.80 +6.65 (1.88%) ULTRACEMCO 11,588.50 +189.15 (1.66%) ONGC 242.20 +2.50 (1.04%) ASIANPAINT 2,338.20 +12.00 (0.52%) BRITANNIA 4,838.15 -11.65 (-0.24%) HDFCLIFE 682.15 +13.65 (2.04%) WIPRO 272.05 +4.80 (1.80%) POWERGRID 294.90 +3.55 (1.22%) BPCL 275.95 +2.85 (1.04%) TITAN 3,085.65 +28.45 (0.93%) Download Unicorn Signals App
By EquityPandit
The US Food and Drug Administration(USFDA), has given approval to Natco Pharma’s marketing partner,Mylan’s Glatiramer Acetate injection used for treating relapsing forms of multiple sclerosis(MS).
In a regulatory filing Natco Pharma stated that, the approval is given for drug in strengths of 40 mg/ml and 20 mg/ml and it is substituable generic version of Teva’s Copaxone.
As per Natco Pharma, Copaxone is the most prescribed MS treatment for relapsing forms in United States.
